Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Am J Kidney Dis. 2009 Mar;53(3):426-37. doi: 10.1053/j.ajkd.2008.09.024. Epub 2008 Dec 19.

Hospital performance and differences by kidney function in the use of recommended therapies after non-ST-elevation acute coronary syndromes.

Author information

  • 1Division of Nephrology, Duke University Medical Center, Durham, NC, USA. patel080@mc.duke.edu

Abstract

BACKGROUND:

Chronic kidney disease (CKD) is associated with an increased risk of cardiac events and death; however, underuse of guideline-recommended therapies is widespread. The extent to which hospital performance affects the care of patients with CKD and non-ST-segment elevation acute coronary syndromes (NSTE ACSs) is unknown.

STUDY DESIGN:

Observational cohort.

SETTING & PARTICIPANTS:

81,374 patients with NSTE ACSs treated at 327 US hospitals.

PREDICTOR:

Hospital performance, measured by quartiles of composite adherence to American Heart Association class I guidelines for therapy acutely (aspirin, beta-blockers, clopidogrel, heparin, and glycoprotein IIb/IIIa inhibitors) and at discharge (aspirin, clopidogrel, angiotensin-converting enzyme inhibitors, and lipid-lowering agents) in eligible patients.

OUTCOMES & MEASUREMENTS:

Use of each American Heart Association class I acute and discharge therapy stratified by continuous estimated glomerular filtration rate (eGFR). Multivariable models were adjusted for demographics, clinical factors, and hospital features.

RESULTS:

Better-performing hospitals had lower prescribing rates for most therapies (5 of 9) with lower levels of kidney function, whereas lower-performing hospitals were more likely to have similar prescribing rates across the eGFR spectrum, suggesting that prescribing patterns at these hospitals were insensitive to differences in eGFR.

LIMITATIONS:

Observational design, selection bias of study cohort.

CONCLUSION:

Patients with lower levels of kidney function admitted with NSTE ACSs are less likely to receive evidence-based therapies. Treatment disparities related to CKD are most evident at top-performing hospitals.

Comment in

PMID:
19100672
[PubMed - indexed for MEDLINE]
PMCID:
PMC2666008
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1
Figure 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk